Heart Doctor Says Merck Suppressed Vioxx Data
Posted on: Tuesday, 6 December 2005, 09:00 CST
By ASSOCIATED PRESS
A prominent cardiologist testifying in Merck & Co.'s federal trial over Vioxx accused the drugmaker of engaging in scientific misconduct, suppressing clinical evidence and stifling medical discourse as it promoted the painkiller.
Dr. Eric Topol, chairman of the cardiovascular medicine department of the Cleveland Clinic, called certain aspects of Merck's behavior "repulsive" and "appalling" during a three-hour videotaped deposition played for the jury Saturday.
Topol said Vioxx can cause heart attacks any time after a patient begins taking it, and that its risks were apparent as early as 1999, when the drug was approved. Vioxx was removed from the market last year after a study showed it doubled patients' risk of heart attacks and strokes after 18 months of use.
The jurors who heard Topol's testimony Saturday will be asked to decide if the drug contributed to the fatal heart attack suffered by Richard "Dicky" Irvin in May 2001. The 53-year old former manager of a seafood wholesaler had been taking Vioxx for about a month for back pain. His widow is suing Merck.
Merck argues that the drug wasn't responsible for Irvin's death, saying problems with Vioxx surface after 18 months of use, not one month, and alleging that plaque in Irvin's artery ruptured and caused the heart attack, not the drug.
Source: Buffalo News
Related Articles
- Heart Drug's Safety Scrutinized
- Heart-Drug Study Reverts to Original Path
- Merck Reports Encouraging Results in Pivotal Heart Drug Study
- Plantation, Fla.-Based Drug Maker, Two Others Win Court Victory for Heart Drug
- Abbott heart drugs show mixed results, shares fall
- Physicians slower to incorporate newer heart drug treatments
- Women under-represented in heart drug trials
- How Many More Victims of Fake Heart Drug Scam?
- After a Long Delay, FDA Approves Warnings for Heart Drug
- Millions Take Heart Drug As Warning of Its Risks is Delayed
User Comments (0)

RSS Feeds